Status:
COMPLETED
Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)
Lead Sponsor:
Dr. Falk Pharma GmbH
Conditions:
Crohn's Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether mesalazine or budesonide is more active in the treatment of active Crohn's disease.
Detailed Description
Crohn's disease is often treated with glucocorticoids or mesalazine. Both drugs are indicated for active Crohn's disease. Treatment with mesalazine is indicated for the treatment of mildly to moderate...
Eligibility Criteria
Inclusion
- Inclusion Criteria (main):
- Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic and histological, or endoscopic and radiological criteria \[endoscopy not older than 12 months or if older, then clinical signs (e.g. pain localization, pain intensity, blood in stool) and behaviour (according to Vienna classification) should be unchanged compared to former episodes\]
- Localisation of CD either in terminal ileum, ascending colon or ileocolitis
- Active phase of disease (200 \< CDAI \< 400)
- Exclusion Criteria (main):
- Known Crohn's lesion in the upper GI-tract (up to and including the jejunum) with present symptoms
- CD in the rectum currently present
- Short bowel syndrome
- Septic complications
- Baseline stool positive for germs causing bowel disease
- Abscess, perforation or active fistulas
- Ileostomy or colostomy
- Resection of more than 50 cm of the ileum
- Bowel surgery within the last 3 months
- Immediate surgery required
- Clinical signs of stricturing disease
- Subileus within the last 6 months
- Suspicion of ileus, subileus or corresponding symptomatology
- Contra-indications, special warnings and precautions mentioned in SmPC
- Treatment with immunosuppressants, cytostatics, 6-TG, methotrexate, or cyclosporine within the last 3 months; in case of treatment with azathioprine or 6-MP the drugs have to be used for maintenance of remission only and dosage has to be unchanged within the last 3 months before baseline visit and during the study
- Treatment with ketoconazole, ciprofloxacin or other CYP3A inhibitors within the last month before baseline visit
- Treatment with anti-TNF-a therapy within 6 months before baseline visit
- Conventional steroids (iv, po, rectal) within 2 weeks before the study
- \> 6 mg/d budesonide po or \> 3 g/d mesalazine po within 2 weeks before the study
- Patients known to be steroid-refractory or steroid-dependent from former CD episodes
- Treatment of study disease with oral antibiotics (e.g., metronidazole) within the last 2 weeks
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
311 Patients enrolled
Trial Details
Trial ID
NCT00300118
Start Date
September 1 2004
End Date
May 1 2008
Last Update
May 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ev. Krankenhaus Hattingen GmbH
Hattingen, Germany, 45525